Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary

April 29, 2021

NASDAQ US Health Care Biotechnology earnings 47 min

Earnings Call Speaker Segments

Holly Manning

executive
#1

Thanks, operator. Greetings, everyone, and welcome to Agios's First Quarter 2021 Conference Call. You can find slides for today's call in the Investors section of our website, agios.com. With me today to give prepared remarks are Dr. Jackie Fouse, our Chief Executive Officer; Dr. Chris Bowden, our Chief Medical Officer; Darrin Miles, our Chief Commercial Officer; and Jonathan Biller, our Chief Financial Officer and Head of Legal and Corporate Affairs. Dr. Bruce Car, our Chief Scientific Officer, will be here for Q&A. Before we begin, I want to remind everyone that certain statements we make on this call will include forward-looking statements. There's a chance that real outcomes and figures might end up noticeably different from anything suggested or predicted in forward-looking remarks, because of a range of dangers, unknowns, and additional influences — among them the ones listed in the documents we filed most recently with the SEC, plus any later filings we might submit to that agency. Having said that, I'll now hand things over to Jackie.

Jacqualyn Fouse

executive
#2

Thank you, Holly. Good morning to all of you, and I appreciate you being on the call for our first quarter 2021 results. This year's opening 3 months proved highly productive; we completed the divestiture of our oncology business, sped up our late-stage clinical programs for mitapivat and got ready for our initial regulatory submissions and the commercial launch that would follow in pyruvate kinase deficiency. Last December, we shared our strategy of concentrating on genetically defined diseases, which includes hastening and revealing the complete promise of mitapivat across its 3 initial indications in hemolytic anemias, along with applying our broader know-how in PK activation and our additional research programs. To make that focus possible, we also revealed our choice to divest our oncology programs to Servier in order to support and finance this strategy. From then until now, close to 1/3 of our company has been hard at work on the critical and intricate task of guaranteeing a seamless handover of our assets and personnel to Servier. Agios shareholders gave their approval to the transaction on March 25. Then on April 1, we shared news that the sale had closed. To all the oncology staff members who, throughout the last decade, helped bring about genuinely meaningful, differentiated therapies for patients, we thank you for your passionate efforts at Agios, and we are eager to see these programs thrive under Servier. Looking forward, Agios stands ready for a promising and sharply focused future that will be built upon the crucial headway we are achieving right now in Q2. That covers completing our worldwide regulatory submissions for mitapivat and pyruvate kinase deficiency; getting set to start 2 Phase III trials of mitapivat in thalassemia and a Phase II/III trial of mitapivat in sickle cell disease; pushing our patient identification work and launch readiness forward before mitapivat could potentially win approval in PK deficiency next year; and last, beginning the careful implementation of as much as $1.2 billion in share repurchases, which Jonathan will explain further. Central to all of this is our ongoing dedication to creating a substantial difference in the lives of the patients we serve. And I want to pause briefly to acknowledge some of the key efforts we have undertaken for patients in recent months. First, we are delighted to announce a collaboration with 23andMe that resulted in the debut of its very first PK deficiency carrier status report, marking a major advance in teaching the wider population about PK deficiency. Second, we announced our sponsorship of Citizen Scientist: Unpacking the Science of Sickle Cell Disease, an initiative created by the Sickle Cell Community Consortium to encourage health literacy among sickle cell patients. As part of the Citizen Scientist Initiative, we also served as the founding sponsor of a fresh set of episodes on Cheat Codes: A Sickle Cell Podcast. That podcast series unites globally recognized physicians with patients and caregivers for genuine discussions about new sickle cell research coming out of major medical and scientific congresses. Our aim is giving those living with sickle cell disease a way to reach essential knowledge regarding improved approaches to handling their wellbeing plus promising novel therapies currently being worked on. The first set of episodes centered on what was shared at the 2020 ASH Annual Meeting, and you can find them by looking up Cheat Codes on whichever platform you use to listen to podcasts. Then third, to mark Rare Disease Day, we put together a conversation on thalassemia featuring Dr. Sujit Sheth — he leads the New York Comprehensive Thalassemia Center — along with his patient Sam, who has undergone treatment for thalassemia for more than 20 years and brings a distinctive viewpoint on what it's like to live with this condition; through these educational and patient-centered initiatives, we show how dedicated we are to creating a meaningful impact on the lives of those we serve. Having said that, I'll hand things over now to Chris.

Chris Bowden

executive
#3

Appreciate that, Jackie. I'll begin with mitapivat, the program for genetically defined disease that's furthest along — our first-in-class PKR activator, which right now is being studied in 3 separate chronic hemolytic anemias: pyruvate kinase deficiency, thalassemia, and sickle cell disease. For pyruvate kinase deficiency, we shared top line results from the Phase III ACTIVATE and ACTIVATE-T studies, which looked at mitapivat in adults with that condition who aren't regularly transfused and those who are regularly transfused, respectively. We're eager to present findings from both trials, among them patient-reported outcomes data, at the European Hematology Association Virtual Congress, taking place June 9 through 17. Such findings back mitapivat's potential to become the first disease-modifying therapy for PK deficiency, and they'll serve as the foundation for the global regulatory filing now underway; we remain on schedule to submit for approval in the U.S. this quarter and in the EU at midyear, with possible 2022 approvals in both regions. Darrin will address our commercial launch preparations during his remarks. Turning to the Phase II thalassemia study of mitapivat: enrollment finished last year at 20 patients, and in June, at EHA, we'll share data covering every patient from that study's core period. Given the strong proof-of-concept results from this trial, we designed 2 worldwide placebo-controlled pivotal studies of mitapivat in thalassemia — ENERGIZE and ENERGIZE-T — which we introduced in December. ENERGIZE will assess 171 patients randomized 2:1 to 100 milligrams of mitapivat BID or placebo, among both beta and alpha thalassemia patients who aren't regularly transfused. Its primary end point is the percentage of patients achieving a mean hemoglobin rise of at least 1 gram per deciliter from baseline across a 24-week core period. ENERGIZE-T will assess 240 patients randomized 2:1 to 100 milligrams of mitapivat BID or placebo, among both beta and alpha thalassemia patients who are regularly transfused, meaning 6 to 20 RBC units transfused in the 24 weeks before randomization. Its primary end point is the percentage of patients seeing a reduction of 50% or more in transfusion burden during any 12-week rolling period within the 48-week core period. We're currently submitting these protocols around the world and getting sites ready to enroll. We expect to launch both trials before the year is out; now, on to sickle cell disease. Last year, mitapivat became the first PKR activator showing proof-of-concept in this condition, drawing on initial data from a study run with Dr. Swee Lay Thein of the National Institutes of Health; and during our previous quarterly results call, we gave an update on regulatory feedback regarding our pivotal plans and introduced our Phase II/III clinical trial, which we believe lowers the risk along the approval path for mitapivat in this difficult disease while raising the odds of a label carrying a broad indication. Our Phase II/III trial of mitapivat in adults with sickle cell disease is designed to be operationally seamless. Enrollment will cover individuals aged 16 and above who experienced 2 to 10 sickle cell crises within the prior 12 months and whose hemoglobin measures between 5.5 and 10.5 grams per deciliter at screening. In the Phase II portion, 69 patients will be assigned randomly in a 1:1:1 ratio to either 50 milligrams of mitapivat BID, 100 milligrams of mitapivat BID, or matching placebo. The primary end point is hemoglobin response, which is defined as a change of at least 1 gram per deciliter from baseline to week 12; those data will help establish a clear dosing paradigm for the Phase III portion. The Phase III, beginning after the Phase II analysis, will randomize 198 patients 2:1 to a selected Phase II dose of mitapivat or matching placebo. This study has 2 primary end points: hemoglobin response, defined as a change of greater than or equal to 1 gram per deciliter from baseline to week 52, and the annualized rate of sickle cell pain crises. We're currently operationalizing this study and remain on track for initiation by the end of the year. Additionally, we continue working with collaborators at the NIH and the University of Utrecht on their mitapivat studies in sickle cell disease. Results from both are anticipated at medical meetings later this year. At the NIH, Dr. Thein has finished enrollment in the core study with 17 patients and is still enrolling participants into the extension study. Supporting our hypothesis that mitapivat could become a novel therapy for sickle cell disease patients, I'm happy to report that, together with investigators from the University Medical Center in the Netherlands, we recently published a manuscript in blood examining the ex vivo effect of mitapivat on red blood cells from sickle cell disease patients and healthy controls. Red blood cells isolated from sickle cell disease patients exhibited reduced pyruvate kinase activity relative to controls because of decreased stability of PKR. Treating isolated sickle cell red blood cells with mitapivat restored pyruvate kinase activity, which led to a reduction in 2,3-DPG and cell sickling behavior. This publication matters because, first, it indicates that compromised red blood cell metabolism might contribute to the complex pathophysiology of sickle cell disease; and second, it offers mechanistic support for mitapivat as a potential novel therapy for sickle cell disease. In addition to mitapivat, we're advancing our next-generation PKR activator, AG-946, in a Phase I healthy volunteer study. Enrollment started last fall, and we expect to submit data from it for presentation at a medical meeting by the end of the year. Our analysis of the totality of AG-946 healthy volunteer data will guide next steps for clinical development of this molecule. With that, I'll hand it over to Darrin to discuss our commercial activities.

Darrin Miles

executive
#4

Thanks, Chris. To start, I'll give a quick look back at how the consumer business performed in Q1 — the final quarter for which Agios carries responsibility for product sales. After that, I'll walk through where we stand on preparing across functions to launch, should mitapivat win approval in 2022. TIBSOVO net sales came in at $37 million for Q1, mostly powered by greater market use in newly diagnosed and relapsed/refractory AML, partly offset by larger expenses tied to Q1 Part D coverage gap seasonality and more volume flowing through Part D institutions. Now to mitapivat launch readiness. Our team advanced on several fronts, among them educating PK deficiency patients, profiling physicians and patients, and the field build that continues. Back in November, we announced the Anemia ID program's launch — a collaboration with PerkinElmer offering no-cost genetic testing so patients and physicians can arrive at a definitive diagnosis when hereditary anemia is suspected. Response to the program has been favorable, and it's being used more and more to assist patients in getting diagnosed by making simpler the testing steps required to reach a definitive diagnosis of a patient's hemolytic anemia. The program additionally gives Agios identified patient-level data, which contributes meaningfully to how we understand the PK deficiency patient profile. What we've seen through this program underscores how large the unmet need is in the community and the growing urgency around better diagnosing patients who have hemolytic anemias, such as PK deficiency. As Jackie noted, in March, 23andMe introduced a new PK deficiency carrier status report into its library of genetic insights and tools. Members who are carriers or homozygous for the R486W variant and the PKLR gene — the most common Southern European PKR variant — get an invitation to receive the customized report containing further information about their risk of developing PK deficiency plus additional resources. A summary of PK deficiency signs and symptoms, along with other relevant clinical and genetic information, is included in the report; we anticipate that some patients who are carriers will pursue genetic counseling for more robust testing, possibly via Anemia ID and other mechanisms, leading to a definitive diagnosis. We've also progressed well in broadening our capacity to give patients with questions important information about PK deficiency; by the end of the quarter, we plan to launch a robust PK deficiency patient education program, run through existing Agios infrastructure, myAgios Patient Support. Patients will be invited by the program to opt in to routine communications with trained staff about information concerning their disease. The launch of the expanded patient education program lines up with the anticipated completion of building our customer-facing field organization before Q2 ends. Hemolytic anemia specialists and skilled clinical educators will make up the modest-sized field team. Such roles matter for speeding up our understanding of physicians who treat PK deficiency, the profiles of the patients those physicians treat, and our disease education efforts through virtual and, increasingly, face-to-face interactions as we move into the second half of the year. We expect that these initiatives, plus the expected clearance of an ICD-10 code specific to PK deficiency before this year is over, will greatly speed up how well we understand both how many patients are being diagnosed with PK deficiency currently and what those patients look like. On the whole, readiness for launch remains on schedule, and our progress so far makes us happy. At this point I'll hand things to Jonathan, who will go over the Q1 financials.

Jonathan Biller

executive
#5

Thank you, Darrin. You can find our financial results for the first quarter of 2021 in the press release that went out this morning, and I'll walk through the highlights. Additional specifics will be provided in the 10-Q we file later today. As Jackie noted, the oncology business was sold to Servier, with the deal closing on March 31, so the first quarter figures tied to that oncology business appear in the discontinued operations note within our financial statements. Let me begin by discussing continuing operations. R&D spending for the first quarter came to $57.7 million, which is $2.3 million higher than what we recorded in the first quarter of 2020. That moderate rise in R&D versus the prior year was mainly the result of start-up costs tied to the Phase III trials of mitapivat in thalassemia and sickle cell disease. SG&A expenses for continuing operations totaled $33.1 million in the first quarter, up $1.5 million from the first quarter of 2020. This SG&A increase stemmed largely from certain onetime workforce expenses. Turning to discontinued operations, total revenue for the first quarter reached $41.4 million, including $37 million in net sales of TIBSOVO. Discontinued operations also include $50.2 million of operating expenses, mostly professional fees and workforce costs connected directly to the Servier transaction. We finished the quarter with $2.4 billion in cash, cash equivalents and marketable securities. We anticipate that this cash balance, along with expected interest income, future mitapivat product sales and TIBSOVO royalties, will support our current operating plan through major catalysts and to cash flow positivity, without any need to raise additional equity. As we've said before, our Board of Directors authorized buying back up to $1.2 billion of our outstanding shares using proceeds from the oncology business sale. Earlier this month, we completed the repurchase of roughly 7.1 million shares of Agios common stock held by BMS and its affiliates, for a total purchase price of $344.5 million, or $48.38 per share; furthermore, we've established a 10b5 to 1 plan intended to efficiently buy back a meaningful portion of the remaining shares by year-end. As usual, we'll report on repurchases under these plans, as well as any open market or privately negotiated repurchases, in our upcoming quarterly earnings reports. With that, operator, please open the line for questions.

Alethia Young

analyst
#6

Congratulations on everything you've accomplished so far. I'd like to spend a moment discussing possible pipeline growth — or label expansion — for mitapivat and possibly for 946 as well. Basically, where do things stand — what's your thinking regarding the new indications you may pursue, given everything you understand about the biology in this area?

Chris Bowden

executive
#7

Alethia, this is Chris Bowden speaking; at this stage we look at pyruvate kinase through 2 lenses. One is the PKR side, and I mentioned during my — you already know the late-stage studies, through which we're seeking approvals in pyruvate kinase deficiency, thalassemia and sickle cell disease. There are a few additional indications we're considering in which pyruvate kinase could be targeted by activating wild type. Several of those involve — there are several, such as hereditary spherocytosis. We also have some interest in myelodysplastic syndrome; anemia associated with myelodysplastic syndrome might be treatable by activating wild-type PKR, once again targeting and enhancing red cell health; and beyond that, we've been discussing how activating PKM2 could unlock many doors and additional indications. Let me pause there and turn it over to Bruce Car, who's joining us on today's call, to say a bit about PKM2. We're eager for the back half of the year, when we'll reveal more on this at Research Day; but Bruce, please give us some added detail.

Bruce Car

executive
#8

Right, thank you so much, Chris. So to draw a parallel: PKR is, naturally, lacking when it comes to PK deficiency within red blood cells, and you see a comparable shortfall across numerous hemolytic anemias. If you examine the tissues where PKM2 gets expressed, its ATP production and its functioning are also irregular across a great many disease states. Thus, starting early last year, our work has focused on mapping where PKM2 appears in tissues and how it participates in a range of disease processes. Building on those efforts, we went on to pinpoint multiple indications that look promising for PKM2. These are genuinely wide-ranging, shaped by where the expression occurs. You find it in the brain, the retina, regenerating muscle, the gut wall, and numerous other tissues. We have been running suitable nonclinical models to assess what potential these disease indications might hold. And in just the past few months, we're beginning to see some highly encouraging data pointing toward indications we might possibly pursue — a good number of which would, naturally, call for partnering, given they sit well beyond our hematology know-how. Hopefully we can discuss these indications at an R&D Day, maybe at some point later in the third quarter; the work is progressing very nicely right now, and a few of these indications are in fact producing spectacular nonclinical results. Whether we can grasp how to translate that, we don't know as yet, but there's considerable promise for many further indications for PKM2.

Mohit Bansal

analyst
#9

I've got a few things to ask. First, on the topic of pricing — and I realize I might come across as repeating myself, since this came up before too. Still, since the launch you're planning is for an ultra-rare condition, PKD, what's your current thinking on how to price it? Because something like sickle cell, also rare, is probably still around 4 years off — 4 years following the PKD indication. Let me stop there.

Darrin Miles

executive
#10

Darrin here. You're not repeating yourself at all. I'm glad to take any pricing questions. I'm not going to reveal what price we have in mind. That said, I can offer a few signals about our approach, correct? As you're aware, this is an ultra-orphan indication. Our pricing will mirror the clinical value, especially given that we now have data from both Phase III studies, and we're setting it in a way that captures or mirrors the clinical value for this patient population. And as we've said previously, what we took away from our conversations with the payer community is our belief that such pricing ought to stretch to thalassemia as well. Turning to sickle cell, the payer mix differs, the patient population mix differs, and the related payer mix shifts too. So we might potentially tweak the price for the sickle cell market. As things stand, though, we believe the price we launched with for PKD will hold up nicely into fall, and after that we'll take another look when we move into sickle cell.

Jacqualyn Fouse

executive
#11

One more point to make. Mohit, Jackie here. Like Darrin mentioned, our sickle cell pricing will likewise be determined by the full body of clinical evidence out of the pivotal program in sickle cell. So we'll have to wait and find out what that produces regarding each of the two endpoints we've designed into that study.

Mohit Bansal

analyst
#12

That's quite useful, and if I could squeeze in one more, likely directed at Jackie once more. Considering your robust balance sheet, and even with the buyback initiative, a substantial amount of cash would still remain. Therefore, when you consider your pipeline alongside available funds, do you believe external possibilities might also be worth exploring? Or do you feel your current workload with the preclinical and clinical efforts is already sufficient?

Jacqualyn Fouse

executive
#13

I'd say one of the most thrilling aspects of where we stand as we embark on the next phase of our Agios journey is simply how many assets sit in our pipeline, plus certain prospects Bruce mentioned, where I believe we'll begin to see backing for them and where they could potentially take us, along with the indications Chris pointed out for possibly mitapivat, 946, where you could advance fairly swiftly into the clinic. So we possess an enormous number of things that we fully own, whose chemical matter we understand deeply, as well as the biology and all the rest. Thus, those rank as our highest priorities at present. That said, we do monitor other developments out there, and we don't wish to overlook anything that could be complementary or pertinent to us. We consistently do this and will keep doing so. So the chance that we might act on the early side isn't impossible, since that has somewhat been our sweet spot. Yet we have an enormous number of things we consider quite exciting happening right now, and those are truly what our team is concentrating on. Thanks.

Peter Lawson

analyst
#14

Peter, thanks — this one's for Jonathan, and it's about the buyback: how soon do you expect to move on it, do you have a target share count in mind as you look toward year-end, and when does that repurchase activity begin?

Jonathan Biller

executive
#15

Absolutely, and thanks for raising it. As we've discussed previously, we're off to a solid start on our repurchase program — we were able to negotiate buying back that 10% stake held by Bristol, and we believe the price we secured was a favorable one. Near that same period, we established arrangements of our own to conduct market purchases via 10b5-1 plans. The plan currently in effect, which I believe we've already made public, allows for as much as $600 million in buybacks, and when that happens hinges on whether our algorithms and similar mechanisms are up and running. So movement in the share price and comparable factors will influence it. Even so, our expectation is that once the year ends, counting the Bristol stake, we'll have completed more than half — or at least half — of the buybacks we plan to carry out. Pinpointing the precise figure is difficult, since it partly hinges on how much volatility shows up in our stock as well as in the broader macro environment.

Peter Lawson

analyst
#16

Excellent. Then a fast one, perhaps for Jackie or Chris, regarding the collaboration involving 23andMe that concerns carrier status for PK deficiency. Do you believe that effort was going to be of assistance? And has it brought about any sort of improved comprehension regarding both how frequently PKD occurs and its incidence?

Jacqualyn Fouse

executive
#17

Right. In my view, Darrin is ideally positioned to respond to that. Would you like to chime in, Darrin? Or...

Darrin Miles

executive
#18

Absolutely, glad to do that. So yes, I believe it contributes significantly to what we know about the patient's overall profile. One thing worth pointing out: the 23andMe chip examines a single variant. That variant matters, and it's the one most frequently cited in published literature. But as you may remember, we identified roughly 300 mutations for PKD. So although it's valuable and provides us with quite meaningful insights drawn from the population that has undergone 23andMe testing, it clearly wouldn't be enough, correct? That's why we're still examining numerous sources so we can gain a clearer picture of how prevalent this disease truly is. Still, everything we've observed so far is quite encouraging, at least within the 23andMe data set. And the fact that those patients who turn out to be carriers or homozygous for the 486 mutation or variant receive direct information helping them understand what steps they should take accordingly, correct? We've also established other mechanisms or channels for those patients so they can potentially seek further genetic testing through Anemia ID. And ultimately, once we launch myAgios PK — or as part of the kinase deficiency patient support program, possibly by the close of this quarter — those patients will then choose to enroll in our patient support program, which will let them obtain timely information regarding their disease and, following approval, gain access to mitapivat.

Tessa Romero

analyst
#19

Tessa here, calling in for Anupam. Only one question from our side. Could you refresh our memory on whether any other important analyses will be featured at EHA in June that we ought to watch closely, particularly for the thalassemia or PKD programs?

Chris Bowden

executive
#20

Yes; Chris Bowden speaking. I believe that — regarding part of a kinase deficiency, this marks the initial occasion where data from the pivotal trials, ACTIVATE and ACTIVATE-T, are going to be shared. So I'd say the key analyses are numerous. There are, naturally, the primary end points, plus the safety data. One particularly significant element of ACTIVATE, which is a randomized study; so you'll — for the first time, we'll get to observe the results — the safety findings for mitapivat compared against a placebo-controlled group where both patients and clinicians are blinded. That should provide a far clearer and, I'd argue, well-rounded perspective on how the safety profile appears across a considerable dosing period. Naturally, the patient-reported outcomes in a placebo-controlled trial matter greatly too; so multiple elements of that will be significant. Regarding thalassemia, building upon earlier data we presented to examine how durable those — those hemoglobin responses appear will matter a great deal, since this is yet another program we're advancing into Phase III. And given that we view mitapivat as a drug that keeps showing, with this safety profile, that it can be administered over extended periods, it's suitable for chronic dosing, that durability of responses matters greatly too. I'd say those are the essential elements. Additionally, there will be further data concerning long-term safety with mitapivat, along with other characterizations of the disease burden of pyruvate kinase deficiency; so many analyses will be included, and the overall — I think the comprehensive picture will be broad, covering what we'll present on mitapivat for those 2 diseases.

Mark Breidenbach

analyst
#21

My apologies. Is this coming through? <<inaudible>>

Mark Breidenbach

analyst
#22

Are you able to hear me?

Chris Bowden

executive
#23

Yes. Yes, please continue.

Mark Breidenbach

analyst
#24

No worries at all, and apologies for the hiccup. Turning to the data that your academic partners in sickle cell disease are set to report soon: I'd like to know whether the NIH presentation will feature findings from the extension study, or whether it will probably center on the core study period. Also, regarding the Utrecht study, how many efficacy evaluable patients should we sensibly anticipate? And might you remind us how the Utrecht and NIH trials chiefly differ when it comes to study design?

Chris Bowden

executive
#25

Sure, I'll handle the latter portion first. With the NIH study, you begin — there's a dosing window of 8 weeks, and it runs as 8 weeks of continuous dosing with dose escalation built in, beginning at 5 milligrams, then 20, then 50, then 100, after which comes a taper, and following that patients can enter an extension study. In the Utrecht study, enrollment goes up to 10 patients. They began at 20, then moved to 50, then to 100, and they continue with chronic dosing. So those, I'd say, are the key differences. Broadly speaking, when it comes to trial eligibility criteria, the patient populations are approximately comparable. As for your question about what the NIH will present, that remains uncertain, and I believe it hinges on — it will truly hinge on the number of patients who enter the extension, and how much follow-up has accrued by the time they did their data cut in order to get ready for whichever meeting they intend to submit this to. Let me just note that this is an investigator-sponsored study, meaning they hold the IND and serve as the primary decision-maker on such matters. We work alongside them, and everything is going quite well; however, as of now, they haven't — they have not really turned their attention to working through that degree of detail; as for total evaluable patients in the Utrecht study, the protocol as written indicates they will be seeking at least 10 — up to 10, I should say.

Mark Breidenbach

analyst
#26

All right, understood. And just briefly regarding thalassemia, I'd like to know what the intended split is for the ENERGIZE trials between sites in Europe and those in the U.S.? Also, how much is COVID currently getting in the way of opening clinical sites, particularly across Europe at the moment?

Chris Bowden

executive
#27

We can supply a list of sites, and that will be done during something like the trials in progress type session. So that info is on its way. Right now, we aren't encountering any turbulence when it comes to activating the study and getting it going as far as the pandemic goes; still, we're definitely keeping a close eye on that, since circumstances can shift extremely quickly. But at this point there have been no problems — I'm knocking on wood here at my desk.

Kelsey Goodwin

analyst
#28

Kelsey here, filling in for Michael. We had a few questions about mitapivat in PKD. Since we're now roughly 12 months past launch, how are you viewing the pace of adoption, and how might educational initiatives help speed that up? Also, have you received any early physician reactions to the data so far, perhaps just what was shared in the top-line press releases?

Darrin Miles

executive
#29

Darrin speaking. So — right, we're roughly a year past approval, and we've been growing — adding to the team so we can stay ahead on all the profiling work — patient profiling, physician profiling — which in the end supports adoption once approved. As I said, the entire sales force is now hired. They should be trained and in the field before this quarter ends. We've brought on additional clinical educators as well. We'll also work with practices to assist them in grasping — boosting general awareness and comprehension of the condition. That comes on top of our broadened efforts to find patients, and all of this helps us make sure we possess a solid grasp of the total market, such as how many potentially diagnosed patients there will be by the time approval arrives, and we'll keep those efforts going past approval. Regarding adoption after approval, clearly those patients who are identified — or those doctors whose patients are identified — will be at the top of the list for the team's promotional push. The main factor governing adoption will clearly be how inclined physicians are to prescribe, plus payer management, correct? So writing those policies will take a few months. That matters, yet it doesn't have to become a barrier to uptake. It might simply mean that physicians, before payers have fully put a policy in place or drafted one, need to seek — to step in and help patients obtain access; but that isn't out of the ordinary. It's standard across all approvals; as for early physician reaction to the data set, we've been using anonymized data so we can gather some physician and payer responses to the overall profile, and that's been very encouraging for us. It largely aligns with what we've observed or heard from the community when we relied solely on the target profile data. In fact, given the — what we're seeing in terms of responses, the full profile of the patient population along with the PRO, quality of life data, it's actually even more encouraging in several ways than what we'd heard previously. So overall, I'd say we're positioned well as we head toward approval, and we'll be able to build awareness and excitement around prescribing mitapivat once approval comes through.

Elizabeth Webster

analyst
#30

This is Elizabeth, filling in for Salveen. About the Anemia ID effort, I'm curious — what number of indications could that potentially unlock for you? Also, do you have plans to run initiatives comparable to the 23andMe one for additional rare conditions, and possibly broaden them to cover other PKD variants?

Darrin Miles

executive
#31

Okay, Darrin speaking. Let me take that one first. When it comes to Anemia ID and 23andMe, both of them aim to deepen what we know about PKD in particular. So, for instance — even though the panel utilized in Anemia ID can assist a doctor in spotting any of a range of hemolytic anemias, our attention stays on the data tied to pyruvate kinase deficiency, and on what we see with 23andMe. At this point, we haven't talked about how those efforts could prove useful as we anticipate the broader indications for mitapivat. Still, considering what we saw from the program this fall, and the success — the success we're achieving with PKD, my view is those likely represent workable choices for us when it comes to the extra indications too.

Ernesto Rodriguez-Dumont

analyst
#32

Ernie Rodriguez here, on behalf of Marc. I want to ask something that follows up on what you said earlier about the thalassemia data shown at EHA. On that point — would that data set be big enough, and would follow-up be long enough, for us to begin seeing the effect of the better hemoglobin level? Then my second question is about the ENERGIZE trials: what length of time do you anticipate enrollment will require? Also, should we assume the two trials will follow a comparable schedule? Or does one probably need less time to finish, apart from the fact that the two have different enrollment endpoints?

Chris Bowden

executive
#33

Yes. This is Chris speaking. Thanks for asking. When Dr. Kuo presented our data initially at EHA last year, I believe it showed what we called proof of clinical concept, in which most patients experienced an increase exceeding 1 gram per deciliter; therefore, one key result in today's presentation is that now, 12 months afterward, with 20 patients enrolled and followed longer, how durable those responses are, along with safety, will form a crucial portion of what gets presented. As for the schedules, the schedules for accruing patients in one study compared with the other — it's premature for us to give guidance on that, though I'd point you to the slide shown today, in which our first objective — the objective closest at hand — is getting both studies underway during this year's second half. We remain very much on track for that, with approvals anticipated in the 2025 timeframe. So as matters progress, we can share further specifics. At present, we're only now moving into what I'd describe as the second phase of operations — meaning we've moved past the start of the start, and we're now handling IRBs, working with sites, and so forth. Thus it's premature for us to give guidance about one trial concluding — the schedule for one relative to the other. We establish our schedules very much from thorough feasibility work and then, naturally, monitor matters as they develop. Should we observe significant shifts in either direction — progress speeding up or slowing down — then it falls to us to discuss that once our confidence is solid and to explain what it means. For the moment, though, we're quite encouraged by how we're tracking when it comes to launching the study and holding to our expected approval guidance for 2025.

Jacqualyn Fouse

executive
#34

Appreciate it, operator. I feel a great deal of enthusiasm regarding the strides achieved during this year up to now, which includes handing off our oncology division to Servier; as we step toward what lies ahead as a restructured Agios, beginning with PK deficiency, we anticipate creating a significant impact on the lives of individuals battling illnesses that fall inside the areas we concentrate on. In closing, my gratitude goes out to my fellow Agios team members for the commitment and enthusiasm they bring to improving patients' lives. I'd likewise like to express thanks to every patient, caregiver and physician taking part in our clinical studies. Absent their involvement, our work would be impossible. And thank you all for being here with us today. Farewell.

Operator

operator
#35

This concludes today's conference call. Thank you for participating. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.